<DOC>
	<DOCNO>NCT02448914</DOCNO>
	<brief_summary>This study evaluate continuous addition entacapone infuse levodopa carbidopa pharmacokinetic ( PK ) profile patient advance Parkinson 's disease ( PD ) . All patient receive study drug , i.e . TRIGEL ( levodopa , carbidopa , entacapone ) Duodopa ( levodopa carbidopa ) , randomize order .</brief_summary>
	<brief_title>A Study Compare Plasma Levels Levodopa , Carbidopa Entacapone After TRIGEL Duodopa Infusion PD Patients</brief_title>
	<detailed_description>Intestinal infusion Duodopa ( levodopa carbidopa ) provide fast absorption , comparable levodopa bioavailability significantly reduce intra-patient variability levodopa concentration relative oral administration . TRIGEL also contain third ingredient , entacapone . In tablet form , entacapone show improve bioavailability levodopa might extend half-life levodopa , avoid deep trough levodopa plasma level , provide continuous delivery levodopa brain . The intention study confirm TRIGEL administration increase area curve ( AUC ) levodopa combine levodopa , carbidopa , entacapone thereby low daily levodopa dose need . It expect TRIGEL administration result similar intra-patient variability plasma levodopa concentration Duodopa continuous administration .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>1 . Willing able provide inform consent judged Investigator decisionmaking capacity 2 . Advanced levodoparesponsive idiopathic PD currently treat Duodopa infusion since minimum 30 day 3 . 30 year age old 4 . BMI 17.0 31.0 kg/m2 , inclusive 5 . Agreed use adequate contraceptive measure : Female patient postmenopausal one year female patient childbearing potential use highly efficient method contraception study ( i.e . method le 1 % failure rate [ e.g . sterilisation , hormone implant , hormone injection , intrauterine device , vasectomise partner ] ) . Oral contraceptive combination contraceptive accept . Male patient vasectomise agree use condom study partner use highly efficient method contraception describe . 1 . Hypersensitivity allergy investigational medicinal product ( IMP ) chemically relate product 2 . Contraindications use levodopa carbidopa entacapone 3 . Needing daily total dose Duodopa study participation exceed 125 mL 4 . Increased fluctuation clinical PD symptom within 7 day prior Screening 5 . Administration investigational drug within 3 month prior Screening and/or current participation another clinical study involve pharmaceutical medical device class III 6 . Use forbidden medication specify Section 9.6 protocol 7 . Known hepatitis B , hepatitis C HIV infection 8 . Donation blood plasma major blood loss ( â‰¥500 mL ) within 3 month prior Screening 9 . Positive urine drug test ( amphetamine , benzodiazepine , tetrahydrocannabinol , cocaine opiate ) Screening 10 . Known alcohol abuse 11 . Unwilling meet requirement protocol 12 . Other medical social reason exclusion discretion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>